

CURRICULUM VITAE of MORENO URSINO

Personal information

Surname Name	Ursino Moreno
Address	Paris, France
E-mail	moreno.ursino@gmail.com
Nationality	Italian
Date and place of birth	31-10-1986 Turin (IT)
Website	http://www.morenousino.com



Actual position

December 2018 - present

Research Fellow, Ingénieur de recherche hospitalier (research engineer)
F-CRIN PARTNERS Platform, Assistance Publique-Hôpitaux de Paris, UFR de Médecine Paris Diderot, Site Villemin, 10 avenue de Verdun, 75010 PARIS

Previous position

June 2014 - November 2018

Research Fellow, Postdoctoral position at Inserm UMRS 1138 team 22, Centre de Recherches des Cordeliers, Université Paris Descartes, Sorbonne Université, Paris.

Projects:

InSPiRe (Innovation in Small Populations Research) European project (FP7 funded, June 2014 - May 2017). Member of Work Package 1: research in developing novel methodology for improving dose-finding in early phase clinical trials by incorporating data on pharmacokinetics and pharmacodynamics, multiple toxicities and experts elicitation.

<http://www2.warwick.ac.uk/fac/med/research/hscience/stats/currentprojects/inspire>

Novel methods for meta-analysis of phase I dose-finding early phase clinical trial to better estimate the Maximum Tolerated Dose. Funded by INCa (Institut National du Cancer, June 2017 - November 2018)

September 2017 - November 2018

Consultant as Biostatistician Senior, Unité d'épidémiologie clinique, CIC-EC 1426, Assistance Publique-Hôpitaux de Paris, Hôpital Robert Debré.

Education

PhD

PhD in Mathematics for Engineering Sciences at the Department of Mathematical Sciences "Giuseppe Luigi Lagrange" of Politecnico di Torino, Turin (January 2010 - December 2013).

Research in biostatistics, in particular in statistical genetics and in ordinal data arising from patients (VAS) pain score.

Thesis Title: *Ordinal data: a new model with applications*. Supervisor: Mauro Gasparini.

Master degree

Master of Science in Mathematical Engineering - December 2010, Top grade (Final grade 110/110 cum laude), Politecnico di Torino, Italy.

Thesis: *Statistical algorithms for genome-wide scanning and identification of genes related to latitude*. Supervisor: Mauro Gasparini.

Master degree	Master of Science in Mathematical Engineering - December 2010, Top grade (Final grade 110/110 cum laude), Politecnico di Milano, Italy. Double degree program.
Alta Scuola Politecnica	March 2009 - December 2010. Project: <i>Wireless Intelligent Monitoring Systems for Aquatic Environments (WIMSAE)</i> . Diploma ASP.
Bachelor degree	Bachelor of Arts in Mathematics for Engineering Sciences - October 2008, Top grade (Final grade 110/110 cum laude), Politecnico di Torino, Italy. Thesis: <i>Viscoelastic models in cell aggregates</i> . Supervisor: Luigi Preziosi.

Work and teaching experience

Academic year 2013-2014	Assistant Lecturer, Politecnico di Torino, course in “Probability, Statistics and Safety”, Degree Course in Mathematics for Engineering Sciences. (20 hours). Topics included: Conditional probability, DAG, simulation, delta method, likelihood, Fisher information matrix.
Academic year 2012-2013	Assistant Lecturer and Laboratory Teaching Assistant (R software), Politecnico di Torino, course in “Probability, Statistics and Safety”, Degree Course in Mathematics for Engineering Sciences (20 hours). Topics included: DAG, simulation, likelihood, confidence intervals, regression.
Academic year 2011-2012	Laboratory Teaching Assistant (R Software), course in “Probability and Statistical Models”, Degree Course in Mathematics for Engineering Sciences (10 hours), Politecnico di Torino. Teaching of R software from basic level up to regression and ANOVA.
Academic year 2010-2011	Laboratory Teaching Assistant (R Software), course in “Probability and Statistical Models”, Degree Course in Mathematics for Engineering Sciences (8 hours), Politecnico di Torino. Teaching of R software from basic level up to regression and ANOVA. Laboratory Teaching Assistant (R software), University of Turin, Degree Course in Statistics (28 hours). Teaching of R software from basic level up to regression and ANOVA.
January 2010	Consultant - R Software, Department of Mathematics, Politecnico di Torino. Programming and data analysis (genetic epidemiology).

Students supervised

Master students	Adrien Ollier, March 2016 – August 2016: “A Bayesian model for PK/PD parameters estimation”, ISUP L’Institut de Statistique de l’Université de Paris; Université Pierre et Marie Curie, Master de mathématiques et applications - Spécialité Statistique. Co-supervision with Sarah Zohar (INSERM). Emma Gerard, April 2017 – September 2017: “Dynamic treatment regimens for dose finding studies in oncology”, ENSAI Ecole nationale de la statistique et de l’analyse de l’information. Co-supervision with Sarah Zohar (INSERM), Dr Marie-Karelle Riviere (Sanofi), Dr Christelle Lorenzato (Sanofi) and Dr Aurore Allard (Sanofi)
-----------------	---

Research Fellow	Artemis Toumazi, From April 2016 to February 2018: R packages developer, ingénieur d'études. Co-supervision with Sarah Zohar (INSERM).
PhD	Adrien Ollier, From October 2016: "Bridging information across populations and schedules in early phase clinical trials in oncology", Ecole Doctorale ED 393 Santé publique: épidémiologie & sciences de l'information biomédicale. Co-supervision with Sarah Zohar (INSERM).

Computer skills

Language	C++
Software	R, Matlab, Mathematica, Fluent/Gambit, Comsol, Office (ECDL), Latex, Monolix
Operating system	Windows, Linux, Mac

Linguistic knowledge

Italian	Mother tongue
English	C1
French	B2
Spanish	A2

Communication skills

The ability to relate to, and feel comfortable with, people at all levels and to be able to make and maintain good working relationships gained in the collaboration with different professionals (statisticians, doctors, biologists).

Publications

Publications on International journals	<p>Schmitz, T., Alberti, C., Ursino, M., Baud, O., and Aupiais, C. <i>Full versus half dose of antenatal betamethasone to prevent severe neonatal respiratory distress syndrome associated with preterm birth: study protocol for a randomised, multicenter, double blind, placebo-controlled, non-inferiority trial (BETADOSE)</i>. BMC Pregnancy and Childbirth, 2019 Feb 12;19(1):67.</p> <p>Boulet, S., Ursino, M., Thall, P, Jannot, AS, and Zohar, S. <i>Bayesian variable selection based on clinical relevance weights in small sample studies - Application to colon cancer</i>. Statistics in Medicine, 2019, https://doi.org/10.1002/sim.8107.</p>
--	--

Favrais, G., Ursino, M., Mouchel, C., Boivin, E., Jullien, V., Zohar, S., Saliba, E. *Levetiracetam optimal dose-finding as first-line treatment for neonatal seizures occurring in the context of hypoxic-ischaemic encephalopathy (LEVNEONAT-1): study protocol of a phase II trial.* BJM Open, 2019, <http://dx.doi.org/10.1136/bmjopen-2018-022739>

Friede et al. *Recent advances in methodology for clinical trials in small populations: the InSPiRe project.* Orphanet Journal of Rare Diseases, online October 2018, <https://doi.org/10.1186/s13023-018-0919-y>

Erhardt, E. M., Ursino, M., Biewenga, J., Jacobs, T., Gasparini, M.. *Bayesian knowledge integration for an in vitro–in vivo correlation model.* Biometrical Journal, online September 2018

Ursino, M., Yuan, Y., Alberti, C., Comets, E., Favrais, G., Friede, T., Lentz, F., Stallard, N. and Zohar, S.. *A dose finding design for seizure reduction in neonates.* JRSS C, 2019 68, Part2, pp.427–444 (online May 2018)

Toumazi, A., Comets, E., Alberti, C., Friede, T., Lentz, F., Stallard, N., Zohar, S., Ursino, M.. *dfpk: An R-package for Bayesian dose-finding designs using pharmacokinetics (PK) for phase I clinical trials.* Computer Methods and Programs in Biomedicine, Volume 157, April 2018, Pages 163-177

Shing, M.L, Ursino, M., Cheung, Y.K. and Zohar, S.. *Dose-finding designs for cumulative toxicities using multiple constraints.* Biostatistics, 2019 Jan 1;20(1):17-29 (online 2017)

Thall, P.*, Ursino, M.*, Baudouin V., Alberti, C. and Zohar, S.. *Bayesian treatment comparison using parametric mixture priors computed from elicited histograms.* Statistical Methods in Medical Research, 2019, Vol. 28(2) 404–418 (online 2017)

Ursino, M., Zohar, S., Lentz, F., Alberti, C., Friede, T., Stallard, N., and Comets, E. *Dose-finding methods for Phase I clinical trials using pharmacokinetics in small populations.*” Biometrical journal, 2017 Jul; 59(4):804-825. doi: 10.1002/bimj.201600084

Petit, C., Samson, A., Morita, S., Ursino, M., Guedj, J., Jullien, V., Comets, E., and Zohar, S.. *Unified approach for extrapolation and bridging of adult information in early phase dose-finding paediatric studies.* Statistical Methods in Medical Research, 2018 Jun;27(6):1860-1877 (online 2016)

Ursino, M., and Gasparini, M.. *A new parsimonious model for ordinal longitudinal data with application to subjective evaluations of a gastrointestinal disease.* Statistical Methods in Medical Research, 2018 May;27(5):1376-1393 (online 2016)

Di Gaetano, C., Matullo, G., Piazza, A., Ursino, M., and Gasparini, M. *A Proximity-Based Method to Identify Genomic Regions Correlated with a Continuously Varying Environmental Variable.* Evolutionary Bioinformatics online, 2013: vol. 9, pp. 29-42. - ISSN 1176-9343

PhD Thesis. M. Ursino. Ordinal data: a new model with applications. 2014 Link: <http://porto.polito.it/id/eprint/2535701>

Manuscripts

Presentations and Posters (presented by myself)

Presentations

(invited) *Dose-finding designs incorporating PK information or multiple toxicity constraints*, Servier - Symposium on Innovative statistical methods in Oncology, Suresnes (Paris - FR), February 2019

Speed: Novel design methods to use PK for improved dose-finding in early phase clinical trials, JSM, Vancouver (CA), August 2018

(invited) *Bayesian treatment comparison using parametric mixture priors based on histograms elicited from expert physicians*, LSHTM - CSM, London (UK), July 2018

Bayesian treatment comparison using parametric mixture priors based on histograms elicited from expert physicians, ISBA, Edinburgh (UK), June 2018

(invited) *Novel design methods to use PK for improved dose-finding in early phase clinical trials*, PKUK, Great Malvern (UK), November 2017

(invited) *Incorporating pharmacokinetic information in phase I studies in small populations*, CEN-ISBS, Vienna, August 2017

(invited) *Bayesian treatment comparison using parametric mixture priors based on histograms elicited from expert physicians*, Center for Medical Statistics, Informatics and Intelligent Systems, Vienna, Austria, May 2017

Bayesian treatment comparison using parametric mixture priors based on histograms elicited from expert physicians, Epiclin, Saint-Étienne, France, May 2017

(invited) *A Bayesian weighted pseudo-likelihood design for Phase I/II clinical trial in newborns with seizures*, ICTMC, Liverpool, UK, May 2017

(invited) *PK/PD information in early phase dose-finding trials in small populations*, InSPiRe conference, Coventry, UK, April 2017

(invited) *Incorporating pharmacokinetic information in phase I studies in small populations*, EMA meeting, London, March 2017

A Bayesian weighted quasi-likelihood design for Phase I/II clinical trial with repeated dose administration in preterm newborns, Torino, Italy September 2016

A Bayesian weighted quasi-likelihood design for Phase I/II clinical trial with repeated dose administration in preterm newborns, Birmingham, UK August 2016

(invited) *Incorporating pharmacokinetic information in phase I studies in small populations*, Roche, Basel April 2016

(invited) *Incorporating pharmacokinetic information in phase I studies in small populations*, Columbia University Medical Center, Biostatistics department December 2015

Incorporating pharmacokinetic information in phase I studies in small populations, ISCB, Utrecht August 2015

(invited) *Incorporating pharmacokinetic information in phase I studies in small populations*, PODE, Cambridge UK July 2015

Posters

dfpk: an R package for a practical implementation of PK measurements in dose-finding studies. PAGE 2017

Evaluating phase I studies in small populations when incorporating pharmacokinetic information. PAGE 2016

Incorporating pharmacokinetic information in phase I studies in small populations. PAGE 2015

Event organized

2016

5th Early Phase Adaptive Trials Workshop, September 29 - October 1st, 2016, Turin.
 Organizing Committee: Elvira Erhardt, Mauro Gasparini, José Jiménez and Moreno Ursino.
<http://calvino.polito.it/~probstat/torino2016/general.html>

Involvement in clinical trials

LEVNEONAT

New design for the LEVNEONAT clinical trial (Levetiracetam Treatment of Neonatal Seizures: Safety and Efficacy Phase II Study), PHRC-I-13-059, Eudra CT identifier 2014-000791-26, Clinical Trail.gov identifier NCT02229123. Principal characteristics: (1) multicenter trial, (2) Principal investigator: Dr Géraldine Favrais (Service de Réanimation Néonatale, CHRU de Tours, Tours, France), (3) Promotor: CHU de Tours, and (4) Funding: PHRC.

NEPHROMYCY

New analyzing tool for NEPHROMYCY (Cyclophosphamide Versus Mycophenolate Mofetil for the Treatment of Steroid-dependent Nephrotic Syndrome in Children) clinical trial, Clinical Trail.gov identifier NCT01092962. Principal characteristics: (1) single center trial, (2) Principal investigator: Dr Véronique BAUDOUIN, (MD Assistance Publique - Hôpitaux de Paris), (3) Promotor: Robert Debré Hospital, AP-HP, and (4) Funding: Assistance Publique - Hôpitaux de Paris.

Betadose

Design and analysis of Betadose (Dose Reduction of Antenatal Betamethasone Given to Prevent the Neonatal Complications Associated With Very Preterm Birth: a Randomized, Multicentre, Double Blind Placebo-controlled Non Inferiority Trial), Clinical Trail.gov identifier NCT02897076. Principal characteristics: (1) multicenter trial, (2) Principal investigator: Pr Schmitz Thomas, (Assistance Publique - Hôpitaux de Paris), (3) Promotor: Robert Debré Hospital, AP-HP, and (4) Funding: Assistance Publique - Hôpitaux de Paris.

LYSYME

Design and analysis of LYSYME. Principal characteristics: (1) monocentric open label phase 1-2 trial, (2) Principal investigator: Pr Saskia Oro, (Assistance Publique - Hôpitaux de Paris), (3) Promotor: Mondor Hospital, AP-HP, and (4) Funding: PHRC-14-0612.

I authorise the use of my personal data in compliance with Legislative Decree 196/03.

Paris, 26/02/2019